<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806737</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002307-18</org_study_id>
    <nct_id>NCT04806737</nct_id>
  </id_info>
  <brief_title>Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease</brief_title>
  <official_title>A Phase IIa, Double-blind, Randomised, Placebo-controlled Study on the Efficacy and Tolerability of a 14-day Treatment With Teriflunomide vs. Placebo in Subjects With Coeliac Disease Undergoing a 3-day Gluten Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will see if the drug teriflunomide (which is in use in other immune&#xD;
      disorder (multiple sclerosis)) can inhibit the immune activation in celiac disease patients&#xD;
      during a 3 day gluten challenge. This will be measured in a blood sample.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a controlled, double-blind, randomised, singlecentre, placebo-controlled, phase IIa&#xD;
      proof-of-concept study on effects of the drug on activation and efflux of gluten specific T&#xD;
      cells using HLA-DQ:gluten tetramers. The study will be conducted with two treatment groups in&#xD;
      the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14&#xD;
      mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing&#xD;
      gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in&#xD;
      treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic&#xD;
      maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adaptive T cell activation</measure>
    <time_frame>Blood sample on the 4th day after a 3 day gluten challenge</time_frame>
    <description>Expression of CD38 on HLA-DQ:gluten tetramer positive T cells</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>IMP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teriflunomide 14 mg tablets, first 7 days 5 tablets once pr day, thereafter 1 pr day for another 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide Oral Tablet</intervention_name>
    <description>The study will be conducted with two treatment groups in the form of a 2:1 parallel group comparison and will serve to compare oral treatment with 14 mg/d teriflunomide vs. placebo in subjects with well-controlled coeliac disease undergoing gluten challenge. The screening period will be up to 8 weeks, followed by a 7-day run-in treatment period with a loading dose of teriflunomide followed by a 6 day therapeutic maintenance dose, an initial 4-week treatment-free follow-up period and a 6 month closing follow-up.</description>
    <arm_group_label>IMP</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Gluten challenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 18-80&#xD;
&#xD;
          -  Willingness to comply with the study procedures and having signed informed, written&#xD;
             consent&#xD;
&#xD;
          -  Previous diagnosis of coeliac disease according to established guidelines based on&#xD;
             positive serology (Endomysium test, IgA-TG2 and/or IgGDGP) and a duodenal biopsy&#xD;
             showing villous atrophy graded as Marsh 3&#xD;
&#xD;
          -  Positive gene test for HLA-DQ2.5&#xD;
&#xD;
          -  Adherence to gluten-free diet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known intolerance to ingredients of teriflunomide or placebo tablets&#xD;
&#xD;
          -  Known intolerance to gluten challenge&#xD;
&#xD;
          -  Known intolerance to cholestyramine&#xD;
&#xD;
          -  Duration of gluten free diet shorter than six months&#xD;
&#xD;
          -  Positive serology (IgA-TG2 below upper level of normal) at screening visit&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Not willing to comply with proper pregnancy control (in females)&#xD;
&#xD;
          -  Concomitant medication that interferes with immune activation (e.g. steroids,&#xD;
             calcineurin inhibitors, biological treatment for inflammatory bowel disease or other&#xD;
             immune disorders, further list is given below)&#xD;
&#xD;
          -  Any other medical condition that in the opinion of the principal investigator makes&#xD;
             the individual unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PÃ¥l-Dag Line, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hoapital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Knut EA Lundin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siv Furholm, BSc</last_name>
    <phone>+4747408122</phone>
    <email>siv.k.b.furholm@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorunn Stamnaes, PhD</last_name>
    <phone>+4798655528</phone>
    <email>jorunn.stamnas@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Gastroenterology</name>
      <address>
        <city>Oslo</city>
        <zip>0881</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Erik A Lundin, MD, PhD</last_name>
      <phone>90980325</phone>
      <email>k.e.a.lundin@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Knut E. A. Lundin</investigator_full_name>
    <investigator_title>Professor, M.D., PhD., Consultant gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Gluten challenge</keyword>
  <keyword>Teriflunomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

